PET imaging of hypoxia-inducible factor-1-active tumor cells with pretargeted oxygen-dependent degradable streptavidin and a novel [18]F-labeled biotin derivative.

Access this Article

Search this Article

Abstract

<Purpose> : We aimed to evaluate the feasibility of using streptavidin–biotin-based pretargeting for positron emission tomography (PET) imaging of hypoxia-inducible factor (HIF)-1-active tumors. <Procedures> : We used POS, a genetically engineered form of streptavidin that selectively stabilizes in HIF-1-active cells, and (4-[18]F-fluorobenzoyl)norbiotinamide ([18]F-FBB), a radiolabeled biotin derivative, for performing a biodistribution study and for PET imaging. The tumoral [18]F-FBB accumulation was compared to the HIF-1-dependent luciferase bioluminescence and HIF-1α immunohistochemical signal. <Results> : [18]F-FBB accumulation was observed in POS-pretargeted tumors in mice (2.85 ± 0.55% injected dose per gram at 3 h), and clear PET images were obtained at the same time point. The tumoral [18]F-FBB accumulation positively correlated with luciferase bioluminescence (R = 0.72, P < 0.05), and most of the area showing [18]F-FBB accumulation corresponded to HIF-1α-positive areas. <Conclusion> : Pretargeting with POS and [18]F-FBB is an effective approach for PET imaging of HIF-1-active areas in tumors.

Journal

  • Molecular imaging and biology

    Molecular imaging and biology 13(5), 1003-1010, 2011-10

    Springer Verlag

Codes

  • NII Article ID (NAID)
    120003824938
  • NII NACSIS-CAT ID (NCID)
    AA11820180
  • Text Lang
    ENG
  • Article Type
    journal article
  • ISSN
    1536-1632
  • Data Source
    IR 
Page Top